Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Operations (2016 - 2025)

KalVista Pharmaceuticals' Cash from Operations history spans 10 years, with the latest figure at 40364000.0 for Q2 2025.

  • For Q2 2025, Cash from Operations fell 167.22% year-over-year to 40364000.0; the TTM value through Apr 2025 reached 135331000.0, down 51.66%, while the annual FY2025 figure was 152907000.0, 71.36% down from the prior year.
  • Cash from Operations for Q2 2025 was 40364000.0 at KalVista Pharmaceuticals, down from 39642000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 15105000.0 in Q2 2024 and bottomed at 40364000.0 in Q2 2025.
  • The 3-year median for Cash from Operations is 27571000.0 (2024), against an average of 29922428.57.
  • The largest annual shift saw Cash from Operations plummeted 50.47% in 2024 before it crashed 167.22% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 19825000.0 in 2023, then plummeted by 99.96% to 39642000.0 in 2024, then decreased by 1.82% to 40364000.0 in 2025.
  • Per Business Quant, the three most recent readings for KALV's Cash from Operations are 40364000.0 (Q2 2025), 39642000.0 (Q4 2024), and 40220000.0 (Q3 2024).